S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Filevine Launches Anti-Hallucination Tools for Legal Research

Courts are sanctioning attorneys nationwide for AI-generated errors that cost careers and compromise trials. To combat this, Filevine has introduced a new citator and anti-hallucination suite within its LOIS platform, designed to verify the existence, accuracy, and legal standing of every citation in an attorney's brief before filing.

Filevine Launches Anti-Hallucination Tools for Legal Research
Photo: Bio & News

The technology addresses the most frequent pitfalls in legal AI: citations that reference non-existent cases or misinterpret the holdings of real ones. By integrating verification directly into the drafting workflow, Filevine aims to replace hours of manual checking with automated precision. The system flags unverified cases and monitors for negative treatments that traditional tools often overlook.

In internal testing against 68 federal filings previously sanctioned for fabricated or misused authority, the LOIS system identified 174 severe errors across 2,073 citations. Furthermore, in a head-to-head comparison, the tool successfully detected 14 cases where holdings had been overruled by opinions that did not explicitly cite the original case—a nuance missed by competing services like Westlaw’s KeyCite and Lexis’ Shepard’s. CEO Ryan Anderson plans to demonstrate these capabilities on September 10, highlighting the shift from reactive discovery to proactive verification.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!